192.450

-1.200 (-0.62%)
Range 192.030 - 200.366   (4.34%)
Open 195.520
Previous Close 193.650
Buy Price 192.450
Buy Volume 9
Sell Price 195.000
Sell Volume 8
Volume 682,480
Value -
Remark
Measurement Type Value
EPS (USD) 0.192
Trailing EPS (USD) 0.113
NAV (USD) 3.599
Cash In Hand (USD) 3.152
Dividend -
Dividend Yield (%) -
PE 1,004.751
Trailing PE 1,696.95
Price / NAV 53.481
Price / Cash In Hand 61.053
Issued & Paid-up Shares 103,413,000
Treasury Shares -
Market Cap (M) 19,901.832
Par Value (USD) n.a.
Beta - 75 Days 2.043
R-Squared - 75 Days(%) 17.13
Beta - 500 Days 0.966
R-Squared - 500 Days(%) 15.9
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 08 May 2021 04:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.

Earnings

Release Date 29 Jul 2021
View All Events

About NOVOCURE LTD

NovoCure Limited (NovoCure) is a commercial-stage oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields (TTFields), for the treatment of solid tumor cancers. Its TTFields is an anti-mitotic treatment. It also focuses on the clinical trials for the use of TTFields in brain metastases, advanced non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. It is engaged in pipeline development for various indications, such as recurrent glioblastoma, diagnosed glioblastoma, brain metastasis, squamous non-small cell lung cancer, ovarian cancer, pancreatic cancer, mesothelioma, breast cancer, cervical cancer, colorectal carcinoma, liver metastases, malignant melanoma, prostate cancer, renal adenocarcinoma and urinary transitional cell carcinoma. It offers Optune, a TTFields delivery system for use as a monotherapy treatment and NovoTTF-100L for NSCLC.

Loading Chart...